Overcoming Isotope Scarcity & Upstream Bottlenecks for Next-Generation Alpha Emitters

  • Addressing precursor vulnerabilities and geopolitical constraints impacting Tb-161, At-211 & Pb-212
  • Mitigating risks from long-lived isotopic impurities on QC, licensing, and clinical operations
  • Scaling production networks through cyclotrons, linear accelerators, and centralized “super-sites” to support commercial demand